A data breach affecting Abbott Laboratories and its subsidiary Exact Sciences is raising serious concerns about patient privacy. Investigation underway.

This article discusses the monumental $385 million settlement involving Abbott Laboratories, following whistleblower allegations regarding infant formula safety violations.

Abbott's second-quarter 2026 results show impressive growth with a 13% increase in sales. The company raises its full-year EPS guidance to a range of $5.45 to $5.60, reflecting robust performance.

Keller Postman wins a $70 million jury verdict for four infants suffering from NEC due to Abbott's formula, marking a significant milestone in legal accountability.

The McCune Law Group has filed a wrongful death lawsuit against Abbott, alleging defects in the FreeStyle Libre 3 devices linked to several fatalities. This marks a serious medical concern for users.

Kahn Swick & Foti, LLC is scrutinizing the proposed sale of Exact Sciences Corporation to Abbott Laboratories, assessing if the offered price is fair for shareholders.

Abbott Laboratories announces its financial results for Q3 2025, demonstrating notable sales growth and reaffirming its full-year guidance, showcasing strong market performance.

The Lateral Flow Assays Market is set to reach $12.52 billion by 2030, driven by increasing demand for rapid diagnostics and innovations in healthcare technology.

The in situ hybridization market is expected to grow significantly, driven by rising cancer rates and advancements in diagnostic techniques. Key players are investing in innovative technologies.

The cardiovascular devices market is set to reach USD 110.39 billion by 2029, growing at a CAGR of 7.3% driven by aging populations and technological advancements.

The Public Health Advocacy Institute has filed a class action lawsuit against Abbott Laboratories over its misleading marketing of toddler milk products, claiming potential harm to child health.